[go: up one dir, main page]

MA50518A - Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1 - Google Patents

Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1

Info

Publication number
MA50518A
MA50518A MA050518A MA50518A MA50518A MA 50518 A MA50518 A MA 50518A MA 050518 A MA050518 A MA 050518A MA 50518 A MA50518 A MA 50518A MA 50518 A MA50518 A MA 50518A
Authority
MA
Morocco
Prior art keywords
insm1
predicting
expression
therapeutic effect
lsd1 inhibitor
Prior art date
Application number
MA050518A
Other languages
English (en)
Inventor
Ryo Hatanaka
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA50518A publication Critical patent/MA50518A/fr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G01N33/575
    • G01N33/5758
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MA050518A 2017-05-31 2018-05-30 Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1 MA50518A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017108422 2017-05-31

Publications (1)

Publication Number Publication Date
MA50518A true MA50518A (fr) 2020-09-09

Family

ID=64454631

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050518A MA50518A (fr) 2017-05-31 2018-05-30 Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1

Country Status (8)

Country Link
US (1) US12435128B2 (fr)
EP (1) EP3633380A4 (fr)
JP (1) JP6915056B2 (fr)
KR (1) KR102291852B1 (fr)
AU (1) AU2018276611B2 (fr)
MA (1) MA50518A (fr)
TW (1) TWI749235B (fr)
WO (1) WO2018221555A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201804121RA (en) 2015-11-27 2018-06-28 Taiho Pharmaceutical Co Ltd Novel biphenyl compound or salt thereof
DK3632443T3 (da) 2017-05-26 2023-09-11 Taiho Pharmaceutical Co Ltd Potentiator af antitumorvirkning ved hjælp af en biphenylforbindelse
RU2765152C2 (ru) 2017-05-26 2022-01-26 Тайхо Фармасьютикал Ко., Лтд. Новое соединение бифенила или его соль
MA50518A (fr) 2017-05-31 2020-09-09 Taiho Pharmaceutical Co Ltd Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1
BR112022008020A2 (pt) 2019-11-13 2022-07-12 Taiho Pharmaceutical Co Ltd Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1
WO2021107855A1 (fr) * 2019-11-28 2021-06-03 Amniotics Ab Spécification de lignée définitive de guides de métabolisme pendant une transition d'endothéliale à hématopoïétique
EP4393919A1 (fr) * 2022-12-27 2024-07-03 Exscientia Al Limited Modulateurs de lsd1

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801518D0 (sv) 1988-04-22 1988-04-22 Astra Pharma Prod A novel process
US6225049B1 (en) * 1992-06-17 2001-05-01 The United States Of America As Represented By The Department Of Health And Human Services Human insulinoma-associated cDNA
CA2469649C (fr) 2001-12-13 2011-05-03 Natrogen Therapeutics, Inc. Derives d'isoindigo, d'indigo et d'indirubine et utilisation de ceux-ci dans le traitement de cancer
EP2206517B1 (fr) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Compositions immunostimulantes contenant un anticorps anti-PD-L1
EP1792622A1 (fr) 2005-11-11 2007-06-06 GPC Biotech AG Thérapie combinée antiproliférative comprenant un agent chimiothérapeutique à base de platine et d'inhibiteurs EGFR ou d'analogues de la pyrimidine
WO2010017047A1 (fr) 2008-08-05 2010-02-11 Merck & Co., Inc. Composés thérapeutiques
EP2350317A4 (fr) 2008-10-20 2012-06-27 Univ Colorado Regents Marqueurs biologiques prédictifs d une réponse anticancéreuse à des inhibiteurs de récepteur kinase de facteur de croissance 1 de type insuline
WO2010077624A1 (fr) 2008-12-09 2010-07-08 Merck Sharp & Dohme Corp. Biaryl carboxamides
JP2012524280A (ja) 2009-04-17 2012-10-11 オーエスアイ・ファーマシューティカルズ,エルエルシー 上皮成長因子受容体キナーゼ阻害剤に対する抗がん反応を予測するための生物学的マーカー
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
CN102985402B (zh) 2010-04-20 2015-04-29 罗马大学 反苯环丙胺衍生物作为组蛋白去甲基酶lsd1和/或lsd2的抑制剂
EP3375775A1 (fr) * 2010-07-29 2018-09-19 Oryzon Genomics, S.A. Inhibiteurs de déméthylase de lsd1 a base de arylcyclopropylmines et leur utilisation médicale
PE20141322A1 (es) 2011-03-25 2014-10-05 Glaxosmithkline Intellectual Property (N 2) Limited Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina
US9345767B2 (en) * 2011-05-16 2016-05-24 Taiho Pharmaceutical Co., Ltd. Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and EGFR inhibitor
EP3736265A1 (fr) 2011-10-20 2020-11-11 Oryzon Genomics, S.A. Composés (hétéro)aryl cyclopropylamine comme inhibiteurs de lsd1
WO2014151761A1 (fr) 2013-03-15 2014-09-25 Ariad Pharmaceuticals, Inc. Nouveaux inhibiteurs de choline kinase
BR112016002496B1 (pt) * 2013-08-06 2022-07-12 Imago Biosciences Inc. Composto e composição farmacêutica
US9266907B2 (en) 2013-09-05 2016-02-23 King Abdullah University Of Science And Technology Tunable rare-earth fcu-metal-organic frameworks
SMT202300014T1 (it) 2013-12-11 2023-05-12 Celgene Quanticel Research Inc Inibitori della demetilasi lisina-specifica-1
WO2015103060A1 (fr) 2014-01-06 2015-07-09 Algomedix, Inc. Modulateurs de trpa1
AU2015253040B2 (en) 2014-05-01 2020-04-09 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
EP3185858A4 (fr) 2014-08-25 2017-12-27 University of Canberra Compositions pour moduler les cellules souches cancéreuses et leurs utilisations
BR112017004334A2 (pt) 2014-09-05 2018-08-07 Celgene Quanticel Res Inc inibidores de desmetilase específica de lisina-1.
CN107750167B (zh) 2015-04-20 2021-05-25 效应物治疗公司 用于治疗癌症和感染的免疫检查点调节剂的抑制剂
WO2017013061A1 (fr) * 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarqueurs associés à des inhibiteurs de lsd1 et utilisations de ceux-ci
CN105233292B (zh) * 2015-10-19 2018-03-13 中国科学院北京基因组研究所 Ory‑1001联合放疗和化疗用于治疗人三阴性乳腺癌的用途
SG11201804121RA (en) 2015-11-27 2018-06-28 Taiho Pharmaceutical Co Ltd Novel biphenyl compound or salt thereof
US20200069677A1 (en) * 2016-12-09 2020-03-05 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
WO2018136961A1 (fr) 2017-01-23 2018-07-26 Syros Pharmaceuticals Inc. Méthodes de traitement de patients à l'aide d'un agoniste du récepteur alpha de l'acide rétinoïque et d'un anticorps anti-cd38
RU2765152C2 (ru) 2017-05-26 2022-01-26 Тайхо Фармасьютикал Ко., Лтд. Новое соединение бифенила или его соль
DK3632443T3 (da) 2017-05-26 2023-09-11 Taiho Pharmaceutical Co Ltd Potentiator af antitumorvirkning ved hjælp af en biphenylforbindelse
MA50518A (fr) 2017-05-31 2020-09-09 Taiho Pharmaceutical Co Ltd Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1
LT3644999T (lt) 2017-06-30 2023-03-10 Celgene Corporation 2-(4-chlorfenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il) metil)-2,2-difluoracetamido kompozicijos ir panaudojimo būdai
WO2019075327A1 (fr) * 2017-10-12 2019-04-18 Dana-Farber Cancer Institute, Inc. Traitement du carcinome à cellules de merkel
US11685782B2 (en) 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
AU2018377852B2 (en) 2017-11-29 2022-03-24 Epiaxis Therapeutics Pty Ltd Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist
WO2019136016A1 (fr) 2018-01-02 2019-07-11 Celgene Corporation Isotopologues de 2-(4-chlorophényl)-n-((2-(2,6-dioxopipéridin-3-yl)-1-oxoisoindolin-5-yl)méthyl)-2,2-difluoroacétamide
KR102737283B1 (ko) 2019-07-17 2024-12-03 서밋 (옥스포드) 리미티드 리디닐라졸 및 이의 결정 형태의 제조방법
BR112022008020A2 (pt) 2019-11-13 2022-07-12 Taiho Pharmaceutical Co Ltd Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1
AU2021230575A1 (en) 2020-03-06 2022-10-20 Celgene Quanticel Research, Inc. Combination of an LSD-1 inhibitor and nivolumab for use in treating SCLC or sqNSCLC

Also Published As

Publication number Publication date
AU2018276611A1 (en) 2020-01-16
AU2018276611B2 (en) 2022-01-06
US12435128B2 (en) 2025-10-07
JPWO2018221555A1 (ja) 2020-05-21
KR20200007975A (ko) 2020-01-22
WO2018221555A1 (fr) 2018-12-06
US20200190175A1 (en) 2020-06-18
EP3633380A1 (fr) 2020-04-08
KR102291852B1 (ko) 2021-08-23
TWI749235B (zh) 2021-12-11
JP6915056B2 (ja) 2021-08-04
TW201907162A (zh) 2019-02-16
RU2019144056A (ru) 2021-07-02
EP3633380A4 (fr) 2021-02-24
RU2019144056A3 (fr) 2021-07-02

Similar Documents

Publication Publication Date Title
EP3633380A4 (fr) Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1
IL283639A (en) Kif18a inhibitors
IL282794A (en) Therapeutic methods
MA54550A (fr) Inhibiteurs de kif18a
EP3857879A4 (fr) Simplification de prédiction inter-intra combinée
EP3952243A4 (fr) Procédé et appareil d'accès aléatoire
IL262814A (en) Combination therapies of hdac inhibitors and pd-1 inhibitors
MA44725A (fr) Formulations d'un inhibiteur de lsd1
MA52812A (fr) Inhibiteurs de sarm1
FR3052891B1 (fr) Procede d'estimation du facteur d'intensite des contraintes et procede de calcul de duree de vie associe
EP3624804A4 (fr) Inhibiteurs des histone désacétylases (hdac)
EP3745802A4 (fr) Procédé et dispositif d'accès aléatoire
PL3662234T3 (pl) Urządzenie i sposób ulepszonego monitorowania oprysku
EP3801499A4 (fr) Inhibiteurs de sarm1
MA52813A (fr) Inhibiteurs de sarm1
HUE063986T2 (hu) Eljárás és berendezés predikcióhoz
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3817736A4 (fr) Inhibiteurs de pikfyve
MA49006A (fr) Inhibiteurs d'ip6k
HUE062990T2 (hu) DMVR és BDOF alapú inter predikciós eljárás és készülék
MA47305A (fr) Inhibiteurs bicycliques d'histone désacétylase
SG11202006441SA (en) Agents and methods for predicting response to therapy
EP3415524A4 (fr) INHIBITEUR D'EXPRESSION DE L'a-SYNUCLÉINE
FR3026440B1 (fr) Procede de suppression d'effet pogo
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors